GVHD,Acute
12
4
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Role of aGVHD Biomarkers on aGVHD Risks
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Analysis of Intestinal Defensin Expression in Acute GVHD
Safety and Efficacy Study of hAESCs Therapy for aGVHD
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
MAP-guided Preemptive Therapy of aGvHD
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease